文章摘要

文章信息/Info

Title:: Effect of tirofiban hydrochloride on serum hsCRP and matrix metalloproteinases9 levles in patients with acute coronary syndrome

作者:: 周桃; 夏豪; 胡波; 谭安安; 武汉大学人民医院心血管内科，湖北武汉 430060

Author(s):: ZHOU Tao; XIA Hao; HU Bo; TAN Anan; Department of Cadiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China

关键词:: 盐酸替罗非班; 急性冠脉综合征; 超敏C反应蛋白; 基质金属蛋白酶9

Keywords:: tirofiban hydrochloride; acute coronary syndrome; high sensitivity C reactive protein; matrix metalloproteinases9

分类号:: R541.4

DOI:: -

文献标识码:: A

摘要:: 目的观察盐酸替罗非班对急性冠脉综合征（ACS）患者治疗前后血清超敏C反应蛋白（hs-CRP）,基质金属蛋白酶-9（MMP-9）水平的影响，探讨盐酸替罗非班能否抑制斑块炎症反应，及稳定斑块的可能机制。方法 55例初诊为ACS的患者随机分为对照组(n＝31)和试验组(n=24)，试验组在对照组给予口服阿司匹林，氯吡格雷等常规治疗药物的基础上加用静脉滴注盐酸替罗非班，用超敏乳胶增强免疫比浊法测定ACS患者治疗前后hs-CRP水平，酶联免疫反应试剂盒测定MMP-9水平。结果两组治疗前血清hs-CRP,MMP-9水平未见明显差异;两组治疗后hs-CRP,MMP-9水平均显著下降(P<0.01);治疗后,替罗非班组下降更显著(P<0.01)。结论盐酸替罗非班能够显著影响血清hs-CRP, MMP-9水平，从而说明盐酸替罗非班亦能通过抑制血管炎症达到稳定斑块的作用。

Abstract:: AIM To observe the effect of tirofiban hydrochloride on serum hs-CRP and matrix metalloproteinases-9 levels in patients with acute coronary syndrome and to explore its possible mechanism of stabling plaque by inhibiting inflammation in ACS. METHODS Fiftyfive patients were randomly divided into two groups: control group (n=31) and tirofiban group (n=24) treated with tirofiban hydrochloride plus routine medicine. Serum hs-CRP levels were determined by the latex enhanced immunoturbidimetric method. RESULTS The levels of hs-CRP and MMP-9 were significantly different between the two groups after treatment (P<0.01) though no significant difference was found before treatment. Compared to those in control group, serum hs-CRP and MMP-9 significantly decreased in tirofiban hydrochloride group (P<0.01). CONCLUSION Tirofiban hydrochloride can stable the plaque by inhibiting inflammation in ACS.

参考文献/References

［1］ Pamukcu B, Oflaz H, Acar RD, et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation［J］. Throme Thrombolysis, 2005, 20(1):17-22.

［2］ Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase9 and 2 in patients with symptomatic coronary artery disease［J］. Intern Med J, 2005, 35(6):331-335.

［3］ Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases2 and 9 are elevated in patients with acute coronary syndromes［J］. J Am Coll Cardiol, 1998, 32(2):368-372.

［4］ Loftus IM, Naylor AR, Goodall S. Increased matrix metalloproeinase9 activity in unstable carotid plaque. A potential role on acute plaque disruption ［J］. Stroke, 2003, 31(1):40-47.

［5］ Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly［J］. Circ Res, 2002, 90(3):251-262.

［6］ Abe N, Osanai T, Fujiwara T, et al. Creactive proteininduced upregulation of extracellular matrix metalloproteinase inducer in macrophages: Inhibitory effect of fluvastatin［J］. Life Sci, 2006, 78(9):1021-1028.

［7］ Varnava AM, Mills PG, Davies MJ, et al. Relationship between coronary artery remodeling and plaque vulnerability［J］. Circulation, 2002, 105(8):939-943.

我们的网站为什么显示成这样？

盐酸替罗非班对急性冠脉综合征hs-CRP和MMP-9的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics